Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Schwartz, Gregory G; Steg, P Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Goodman, Shaun G; Hanotin, Corinne; Harrington, Robert A; Jukema, J Wouter; Lecorps, Guillaume; Mahaffey, Kenneth W; Moryusef, Angèle; Pordy, Robert; Quintero, Kirby; Roe, Matthew T; Sasiela, William J; Tamby, Jean-François; Tricoci, Pierluigi; White, Harvey D; Zeiher, Andreas M (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 379(22):2097-2107.

Pfeffer, Marc A; Claggett, Brian; Diaz, Rafael; Dickstein, Kenneth; Gerstein, Hertzel C; Køber, Lars V; Lawson, Francesca C; Ping, Lin; Wei, Xiaodan; Lewis, Eldrin F; Maggioni, Aldo P; McMurray, John J V; Probstfield, Jeffrey L; Riddle, Matthew C; Solomon, Scott D; Tardif, Jean-Claude (2015). Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine, 373(23):2247-2257.

Bentley-Lewis, Rhonda; Aguilar, David; Riddle, Matthew C; Claggett, Brian; Diaz, Rafael; Dickstein, Kenneth; Gerstein, Hertzel C; Johnston, Peter; Køber, Lars V; Lawson, Francesca; Lewis, Eldrin F; Maggioni, Aldo P; McMurray, John J V; Ping, Lin; Probstfield, Jeffrey L; Solomon, Scott D; Tardif, Jean-Claude; Wu, Yujun; Pfeffer, Marc A (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 169(5):631-638.

This list was generated on Sun May 26 21:24:35 2019 CEST.